ZetaGen Therapeutics Inc (ZetaGen) is an early stage regenerative medicine company focused on the development of bone growth products for the treatment of bone-related injuries, procedures and diseases. The company's pipeline products include Zeta-BC-003 is for the treatment of bone lesions, inhibit pain and stimulate targeted bone regeneration; Zeta-PC-004 targets metastatic prostate cancer bone lesions; Zeta-MBC-005 treats multifocal breast cancer metastases. It markets its products under Zetagen brand. ZetaGen is headquartered in Syracuse, New York, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company ZetaGen Therapeutics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- ZetaGen Therapeutics Inc Company Overview
- ZetaGen Therapeutics Inc Company Snapshot
- ZetaGen Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
- ZetaGen Therapeutics Inc - Pipeline Analysis Overview
- ZetaGen Therapeutics Inc - Key Facts
- ZetaGen Therapeutics Inc - Major Products and Services
- ZetaGen Therapeutics Inc Pipeline Products by Development Stage
- ZetaGen Therapeutics Inc Ongoing Clinical Trials by Trial Status
- ZetaGen Therapeutics Inc Pipeline Products Overview
- Nalovent Bone Graft
- Nalovent Bone Graft Product Overview
- ZetaDent
- ZetaDent Product Overview
- ZetaFuse
- ZetaFuse Product Overview
- ZetaFuse Clinical Trial
- ZetaMet
- ZetaMet Product Overview
- ZetaMet Clinical Trial
- ZetaSet
- ZetaSet Product Overview
- ZetaGen Therapeutics Inc - Key Competitors
- ZetaGen Therapeutics Inc - Key Employees
- ZetaGen Therapeutics Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- ZetaGen Therapeutics Inc, Recent Developments
- Sep 24, 2024: New Data Published in JAAOS Demonstrates Breakthrough Therapy ZetaFuse as a Potential Treatment for Degenerative Disc Disease in Late-Stage Cancer Patients
- Oct 10, 2023: Zetagen Announces Publication in Pain Management of Early Data Using ZetaMet as a Potential Treatment for Bone Metastases
- Jan 18, 2022: ZetaMet receives Health Canada Authorization for phase 2a study in treating metastatic bone lesions
- Dec 13, 2021: Zetagen Therapeutics awarded $2 million USD grant from the National Cancer Institute (NCI) for phase 2 study of ZetaMet for treatment of metastatic bone cancers
- Dec 01, 2021: ZetaMet receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for treatment of metastatic bone cancers
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- ZetaGen Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
- ZetaGen Therapeutics Inc Pipeline Products by Equipment Type
- ZetaGen Therapeutics Inc Pipeline Products by Indication
- ZetaGen Therapeutics Inc Ongoing Clinical Trials by Trial Status
- ZetaGen Therapeutics Inc, Key Facts
- ZetaGen Therapeutics Inc, Major Products and Services
- ZetaGen Therapeutics Inc Number of Pipeline Products by Development Stage
- ZetaGen Therapeutics Inc Pipeline Products Summary by Development Stage
- ZetaGen Therapeutics Inc Ongoing Clinical Trials by Trial Status
- ZetaGen Therapeutics Inc Ongoing Clinical Trials Summary
- Nalovent Bone Graft - Product Status
- Nalovent Bone Graft - Product Description
- ZetaDent - Product Status
- ZetaDent - Product Description
- ZetaFuse - Product Status
- ZetaFuse - Product Description
- ZetaFuse - Pilot Study of ZetaFuse Bone Graft for the Treatment of Cervical Degenerative Disc Disease
- ZetaMet - Product Status
- ZetaMet - Product Description
- ZetaMet - Ten Patient Pilot Study to Evaluate Safety of the ZetaFuse™ Bone Graft Administered Using an Outpatient Local Intratumoral Injection Procedure to Treat Breast Cancer Bone Metastases in the Spine to Control Pain and Prevent Complications Such as Fracture
- ZetaSet - Product Status
- ZetaSet - Product Description
- ZetaGen Therapeutics Inc, Key Employees
- Glossary
- ZetaGen Therapeutics Inc Pipeline Products by Equipment Type
- ZetaGen Therapeutics Inc Pipeline Products by Development Stage
- ZetaGen Therapeutics Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- EpiBone Inc
- BONESUPPORT Inc.
- Orthofix Holdings Inc
